The dawn of the 20th century saw the formative years of developments in immunology. In particular, immunochemistry, specifically pertaining to antibodies, was extensively studied. These studies laid the foundations for employing antibodies in a variety of ways. Not surprisingly, antibodies have been used for applications ranging from biomedical research to disease diagnostics and therapeutics to evaluation of immune responses during natural infection and those elicited by vaccines. Despite recent advancements in cellular immunology and the excitement of T cell therapy, use of antibodies represents a large proportion of immunotherapeutic approaches as well as clinical interventions. Polyclonal antibodies in the form of plasma or sera continue to be used to treat a number of diseases, including autoimmune disorders, cancers, and infectious diseases. Historically, antisera to toxins have been the longest serving biotherapeutics. In addition, intravenous immunoglobulins (IVIg) have been extensively used to treat not only immunodeficiency conditions but also autoimmune disorders. Beyond the simplistic suppositions of their action, the IVIg have also unraveled the immune regulatory and homeostatic ramifications of their use. The advent of monoclonal antibodies (MAbs), on the other hand, has provided a clear pathway for their development as drug molecules. MAbs have found a clear place in the treatment of cancers and extending lives and have been used in a variety of other conditions. In this review, we capture the important developments in the therapeutic applications of antibodies to alleviate disease, with a focus on some of the recent developments.
Get full access to this article
View all access options for this article.
References
1.
LukeTC, KilbaneEM, JacksonJL, and HoffmanSL: Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?. Ann Intern Med, 2006; 145:599–609.
2.
CasadevallA, and ScharffMD: Serum therapy revisited: Animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother, 1994; 38:1695–1702.
3.
JanewayCA: Use of concentrated human serum gamma-globulin in the prevention and attenuation of measles. Bull N Y Acad Med, 1945; 21:202–222.
4.
HammonWM, CoriellLL, WehrlePF, and StokesJJr.: Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses. J Am Med Assoc, 1953; 151:1272–1285.
5.
KendrickDB: Blood Program in World War II. Office of the Surgeon General, Dept. of the Army: For sale by the Supt. of Docs., U.S. G.P.O, Washington, DC, 1964.
AcostaPLM, SusanHariri, and TejpratapSP: Tiwari: Diphtheria. In: Epidemiology and Prevention of Vaccine-Preventable Diseases, Jennifer Hamborsky AK, Charles (Skip) Wolfe (eds.). Centers for Disease Control and Prevention, Atlanta, GA, USA, 2020, pp. 107–118.
8.
SchusslerE, SobelJ, HsuJ, YuP, Meaney-DelmanD, GrammerLC, 3rd, and Nowak-WegrzynA: Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review. Clin Infect Dis, 2017; 66:S65–S72.
9.
CalmetteA: On snake venom and the use of antivenom in the therapy of bites poisonous in humans and animals [in French]. Ann l'Inst Pasteur, 1897; XII:214–237.
10.
WittekR: Vaccinia immune globulin: Current policies, preparedness, and product safety and efficacy. Int J Infect Dis, 2006; 10:193–201.
11.
DingL, WuM, ZhangH, ZhuX, HuY, LiX, LiuJ, TsaoE, LiuM, and LiC: Safety, pharmacokinetics and pharmacodynamics of SYN023 alone or in combination with a rabies vaccine: An open, parallel, single dose, phase 1 bridging study in healthy Chinese subjects. Antiviral Res, 2020; 184:104956.
12.
WHO: Rabies Monoclonal Antibodies Post Exposure Prophylaxis. World Health Organization, Geneva, Switzerland, 2016.
13.
SzmunessW, StevensCE, OleszkoWR, and GoodmanA: Passive-active immunisation against hepatitis B: Immunogenicity studies in adult Americans. Lancet, 1981; 1:575–577.
14.
NIH: Hepatitis B Immune Globulin (HBIg) to Restore Immune Control in People with Chronic Hepatitis B, 2018, https://clinicaltrials.gov/ct2/show/NCT03575208.
15.
CPS: Varicella zoster immune globulin use in neonates and infants. Can J Infect Dis, 1996; 7:17–18.
16.
ZaiaJA, LevinMJ, PrebludSR, LeszczynskiJ, WrightGG, EllisRJ, CurtisAC, ValerioMA, and LeGoreJ: Evaluation of varicella-zoster immune globulin: Protection of immunosuppressed children after household exposure to varicella. J Infect Dis, 1983; 147:737–743.
17.
BirleaM, OwensGP, EshlemanEM, RitchieA, TraktinskiyI, BosN, SeitzS, AzarkhY, MahalingamR, GildenD, and CohrsRJ: Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection. J Virol, 2013; 87:415–421.
18.
RodriguezJE, MoningerT, and GroseC: Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology, 1993; 196:840–844.
19.
MacagnoA, BernasconiNL, VanzettaF, DanderE, SarasiniA, RevelloMG, GernaG, SallustoF, and LanzavecchiaA: Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol, 2010; 84:1005–1013.
20.
HaS, LiF, TroutmanMC, FreedDC, TangA, LoughneyJW, WangD, WangIM, VlasakJ, NickleDC, RustandiRR, HammM, DePhillipsPA, ZhangN, McLellanJS, ZhuH, AdlerSP, McVoyMA, AnZ, and FuTM: Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH/gL/pUL128-131 pentameric complex. J Virol, 2017; 91:e02033-16.
21.
MaertensJ, LoganAC, JangJ, LongG, TangJL, HwangWYK, KohLP, ChemalyR, GerbitzA, WinklerJ, YehSP, HiemenzJ, ChristophS, LeeDG, WangPN, HollerE, MielkeS, AkardL, YeoA, RamachandraS, SmithK, PertelP, and SegalF: Phase 2 study of anti-human cytomegalovirus monoclonal antibodies for prophylaxis in hematopoietic cell transplantation. Antimicrob Agents Chemother, 2020; 64:e02467-19.
22.
SotoJA, GalvezNMS, PachecoGA, BuenoSM, and KalergisAM: Antibody development for preventing the human respiratory syncytial virus pathology. Mol Med, 2020; 26:35.
23.
MejiasA, Garcia-MaurinoC, Rodriguez-FernandezR, PeeplesME, and RamiloO: Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine, 2017; 35:496–502.
24.
ZhaoY, WangC, QiuB, LiC, WangH, JinH, GaiW, ZhengX, WangT, SunW, YanF, GaoY, WangQ, YanJ, ChenL, PerlmanS, ZhongN, ZhaoJ, YangS, and XiaX: Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Antiviral Res, 2017; 137:125–130.
25.
ZhaoJ, PereraRA, KayaliG, MeyerholzD, PerlmanS, and PeirisM: Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol, 2015; 89:6117–6120.
26.
van GriensvenJ, EdwardsT, de LamballerieX, SempleMG, GallianP, BaizeS, HorbyPW, RaoulH, MagassoubaN, AntierensA, LomasC, FayeO, SallAA, FransenK, BuyzeJ, RavinettoR, TiberghienP, ClaeysY, De CropM, LynenL, BahEI, SmithPG, DelamouA, De WeggheleireA, and HabaN: Evaluation of convalescent plasma for Ebola virus disease in guinea. N Engl J Med, 2016; 374:33–42.
27.
DyeJM, WuH, HooperJW, KhuranaS, KuehneAI, CoyleEM, OrtizRA, FuentesS, HerbertAS, GoldingH, BakkenRA, BrannanJM, KwilasSA, SullivanEJ, LukeTC, SmithG, GlennG, LiW, YeL, YangC, CompansRW, TrippRA, and JiaoJA: Production of potent fully human polyclonal antibodies against Ebola zaire virus in transchromosomal cattle. Sci Rep, 2016; 6:24897.
28.
LukeT, BennettRS, GerhardtDM, BurdetteT, PostnikovaE, MazurS, HonkoAN, OberlanderN, ByrumR, RaglandD, St ClaireM, JanoskoKB, SmithG, GlennG, HooperJ, DyeJ, PalS, Bishop-LillyKA, HamiltonT, FreyK, BollingerL, WadaJ, WuH, JiaoJA, OlingerGG, GunnB, AlterG, KhuranaS, HensleyLE, SullivanE, and JahrlingPB: Fully human immunoglobulin G from transchromosomic bovines treats nonhuman primates infected with Ebola virus makona isolate. J Infect Dis, 2018; 218:S636–S648.
29.
BeigelJH, VoellJ, KumarP, RaviprakashK, WuH, JiaoJA, SullivanE, LukeT, and DaveyRTJr.: Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: A phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis, 2018; 18:410–418.
30.
ChengY, WongR, SooYO, WongWS, LeeCK, NgMH, ChanP, WongKC, LeungCB, and ChengG: Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis, 2005; 24:44–46.
31.
CasadevallA, GrossmanBJ, HendersonJP, JoynerMJ, ShohamS, PirofskiLA, and PanethN: The assessment of convalescent plasma efficacy against COVID-19. Med (NY), 2020; 1:66–77.
32.
DevarasettiPK, RajasekharL, BaisyaR, SreejithaKS, and VardhanYK: A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy. Immunol Res, 2021; 69:18–25.
33.
KhadkaS, NisarS, SyedNI, ShresthaDB, and BudhathokiP: Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review. Immunopharmacol Immunotoxicol, 2021; 43:30–36.
34.
Acosta-AmpudiaY, MonsalveDM, RojasM, RodriguezY, GalloJE, Salazar-UribeJC, SantanderMJ, CalaMP, ZapataW, ZapataMI, ManriqueR, Pardo-OviedoJM, CamachoB, Ramirez-SantanaC, AnayaJM, and groupC-C-: COVID-19 convalescent plasma composition and immunological effects in severe patients. J Autoimmun, 2021; 118:102598.
35.
FeltonLD: The units of protective antibody in antipneumococcus serum and antibody solution. J Infect Dis, 1928; 43:531–542.
36.
WeismanLE, CruessDF, and FischerGW: Opsonic activity of commercially available standard intravenous immunoglobulin preparations. Pediatr Infect Dis J, 1994; 13:1122–1125.
37.
ArabiYM, HajeerAH, LukeT, RaviprakashK, BalkhyH, JohaniS, Al-DawoodA, Al-QahtaniS, Al-OmariA, Al-HameedF, HaydenFG, FowlerR, BouchamaA, ShindoN, Al-KhairyK, CarsonG, TahaY, SadatM, and AlahmadiM: Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis, 2016; 22:1554–1561.
38.
SladeHB: Human immunoglobulins for intravenous use and hepatitis C viral transmission. Clin Diagn Lab Immunol, 1994; 1:613–619.
39.
SatherDN, ArmannJ, ChingLK, MavrantoniA, SellhornG, CaldwellZ, YuX, WoodB, SelfS, KalamsS, and StamatatosL: Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol, 2009; 83:757–769.
40.
GrayES, MadigaMC, HermanusT, MoorePL, WibmerCK, TumbaNL, WernerL, MlisanaK, SibekoS, WilliamsonC, Abdool KarimSS, and MorrisL: The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol, 2011; 85:4828–4840.
41.
AndrewsSF, HuangY, KaurK, PopovaLI, HoIY, PauliNT, Henry DunandCJ, TaylorWM, LimS, HuangM, QuX, LeeJH, Salgado-FerrerM, KrammerF, PaleseP, WrammertJ, AhmedR, and WilsonPC: Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med, 2015; 7:316ra192.
JahrlingPB, FrameJD, RhoderickJB, and MonsonMH: Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg, 1985; 79:380–384.
44.
BosnjakB, SteinSC, WillenzonS, CordesAK, PuppeW, BernhardtG, RavensI, RitterC, Schultze-FloreyCR, GodeckeN, MartensJ, Kleine-WeberH, HoffmannM, CossmannA, YilmazM, PinkI, HoeperMM, BehrensGMN, PohlmannS, BlasczykR, SchulzTF, and ForsterR: Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol, 2020, DOI: 10.1038/s41423-020-00573-9.
45.
BastaM, and DalakasMC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest, 1994; 94:1729–1735.
46.
LutzHU, StammlerP, BianchiV, TruebRM, HunzikerT, BurgerR, JelezarovaE, and SpathPJ: Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood, 2004; 103:465–472.
47.
WidiapradjaA, VeghV, LokKZ, ManzaneroS, ThundyilJ, GelderblomM, ChengYL, PavlovskiD, TangSC, JoDG, MagnusT, ChanSL, SobeyCG, ReutensD, BastaM, MattsonMP, and ArumugamTV: Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. J Neurochem, 2012; 122:321–332.
48.
BayryJ, BansalK, KazatchkineMD, and KaveriSV: DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. Proc Natl Acad Sci U S A, 2009; 106:E24; author reply E25.
49.
BayryJ, Lacroix-DesmazesS, CarbonneilC, MisraN, DonkovaV, PashovA, ChevaillerA, MouthonL, WeillB, BrunevalP, KazatchkineMD, and KaveriSV: Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood, 2003; 101:758–765.
50.
Ruiz de SouzaV, CarrenoMP, KaveriSV, LedurA, SadeghiH, CavaillonJM, KazatchkineMD, and Haeffner-CavaillonN: Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol, 1995; 25:1267–1273.
51.
Park-MinKH, SerbinaNV, YangW, MaX, KrystalG, NeelBG, NuttSL, HuX, and IvashkivLB: FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity, 2007; 26:67–78.
52.
KozickyLK, ZhaoZY, MenziesSC, FidanzaM, ReidGS, WilhelmsenK, HellmanJ, HotteN, MadsenKL, and SlyLM: Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. J Leukoc Biol, 2015; 98:983–994.
53.
GaleottiC, HegdeP, DasM, Stephen-VictorE, CanaleF, MunozM, SharmaVK, DimitrovJD, KaveriSV, and BayryJ: Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin. Sci Rep, 2016; 6:19592.
54.
CasulliS, TopcuS, FattoumL, von GuntenS, SimonHU, TeillaudJL, BayryJ, KaveriSV, and ElbimC: A differential concentration-dependent effect of IVIg on neutrophil functions: Relevance for anti-microbial and anti-inflammatory mechanisms. PLoS One, 2011; 6:e26469.
55.
RuizJE, KwakJY, BaumL, Gilman-SachsA, BeamanKD, KimYB, and BeerAE: Intravenous immunoglobulin inhibits natural killer cell activity in vivo in women with recurrent spontaneous abortion. Am J Reprod Immunol, 1996; 35:370–375.
56.
FinbergRW, NewburgerJW, MikatiMA, HellerAH, and BurnsJC: Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr, 1992; 120:376–380.
57.
Paquin ProulxD, AubinE, LemieuxR, and BazinR: Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clin Immunol, 2010; 135:422–429.
58.
SeiteJF, GoutsmedtC, YouinouP, PersJO, and HillionS: Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J Allergy Clin Immunol, 2014; 133:181–188.e181–e189.
59.
SeiteJF, GuerrierT, CornecD, JaminC, YouinouP, and HillionS: TLR9 responses of B cells are repressed by intravenous immunoglobulin through the recruitment of phosphatase. J Autoimmun, 2011; 37:190–197.
60.
KesselA, PeriR, HajT, SnirA, SlobodinG, SaboE, RosnerI, ShoenfeldY, and ToubiE: IVIg attenuates TLR-9 activation in B cells from SLE patients. J Clin Immunol, 2011; 31:30–38.
61.
SeiteJF, CornecD, RenaudineauY, YouinouP, MageedRA, and HillionS: IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood, 2010; 116:1698–1704.
62.
ZhuangQ, BisottoS, FixmanED, and MazerB: Suppression of IL-4- and CD40-induced B-lymphocyte activation by intravenous immunoglobulin is not mediated through the inhibitory IgG receptor FcgammaRIIb. J Allergy Clin Immunol, 2002; 110:480–483.
63.
de GrandmontMJ, RacineC, RoyA, LemieuxR, and NeronS: Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood, 2003; 101:3065–3073.
64.
BayryJ, MouthonL, and KaveriSV: Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J Rheumatol, 2012; 39:450–451.
65.
MaddurMS, VaniJ, HegdeP, Lacroix-DesmazesS, KaveriSV, and BayryJ: Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol, 2011; 127:823–830.e821–e827.
66.
MaddurMS, KaveriSV, and BayryJ: Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev, 2011; 10:809–810.
67.
MaddurMS, RabinM, HegdeP, BolgertF, GuyM, VallatJM, MagyL, BayryJ, and KaveriSV: Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barre syndrome patients. Immunol Res, 2014; 60:320–329.
68.
SahaC, DasM, PatilV, Stephen-VictorE, SharmaM, WymannS, JordiM, VonarburgC, KaveriSV, and BayryJ: Monomeric immunoglobulin A from plasma inhibits human Th17 responses in vitro independent of FcalphaRI and DC-SIGN. Front Immunol, 2017; 8:275.
69.
SchrageB, DuanG, YangLP, FraserJD, and ProftT: Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: Implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis, 2006; 43:743–746.
70.
BayryJ, Lacroix-DesmazesS, KazatchkineMD, and KaveriSV: Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era?. Trends Pharmacol Sci, 2004; 25:306–310.
71.
Bulletin: I.V. immunoglobulin therapy for infectious diseases. Drug Ther Bull, 2010; 48:57–60.
72.
JonesPT, DearPH, FooteJ, NeubergerMS, and WinterG: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986; 321:522–525.
73.
SmithGP: Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, 1985; 228:1315–1317.
LonbergN, TaylorLD, HardingFA, TrounstineM, HigginsKM, SchrammSR, KuoCC, MashayekhR, WymoreK, McCabeJG, Munoz-O'ReganD, O'DonnellSL, LapachetESG, BengoecheaT, FishwildDM, CarmackCE, KayRM, and HuszarD: Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature, 1994; 368:856–859.
76.
MendezMJ, GreenLL, CorvalanJR, JiaXC, Maynard-CurrieCE, YangXD, GalloML, LouieDM, LeeDV, EricksonKL, LunaJ, RoyCM, AbderrahimH, KirschenbaumF, NoguchiM, SmithDH, FukushimaA, HalesJF, KlapholzS, FinerMH, DavisCG, ZseboKM, and JakobovitsA: Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet, 1997; 15:146–156.
77.
KempeniJ: Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. Ann Rheum Dis, 1999; 58(Suppl. 1):I70–I72.
78.
StohlW, and HilbertDM: The discovery and development of belimumab: The anti-BLyS-lupus connection. Nat Biotechnol, 2012; 30:69–77.
79.
SpratlinJL, CohenRB, EadensM, GoreL, CamidgeDR, DiabS, LeongS, O'BryantC, ChowLQ, SerkovaNJ, MeropolNJ, LewisNL, ChioreanEG, FoxF, YoussoufianH, RowinskyEK, and EckhardtSG: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol, 2010; 28:780–787.
80.
DienstmannR, and TaberneroJ: Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs, 2010; 11:1434–1441.
81.
SofenH, SmithS, MathesonRT, LeonardiCL, CalderonC, BrodmerkelC, LiK, CampbellK, MarciniakSJJr., WasfiY, WangY, SzaparyP, and KruegerJG: Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol, 2014; 133:1032–1040.
82.
KaufmanHL, RussellJ, HamidO, BhatiaS, TerheydenP, D'AngeloSP, ShihKC, LebbeC, LinetteGP, MilellaM, BrownellI, LewisKD, LorchJH, ChinK, MahnkeL, von HeydebreckA, CuillerotJM, and NghiemP: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol, 2016; 17:1374–1385.
83.
BanerjiA, RiedlMA, BernsteinJA, CicardiM, LonghurstHJ, ZurawBL, BussePJ, AndersonJ, MagerlM, Martinez-SaguerI, Davis-LortonM, ZanichelliA, LiHH, CraigT, JacobsJ, JohnstonDT, ShapiroR, YangWH, LumryWR, ManningME, SchwartzLB, ShennakM, SoteresD, Zaragoza-UrdazRH, GiererS, SmithAM, TachdjianR, WednerHJ, HebertJ, RehmanSM, StaubachP, SchranzJ, BaptistaJ, NothaftW, and MaurerM: Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: A randomized clinical trial. JAMA, 2018; 320:2108–2121.
84.
CheloffAZ, and Al-SamkariH: Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. Drugs Today (Barc), 2020; 56:439–446.
85.
JanusA, and RobakT: Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin Biol Ther, 2019; 19:501–508.
86.
AmanP, Ehlin-HenrikssonB, and KleinG: Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med, 1984; 159:208–220.
87.
TraggiaiE, BeckerS, SubbaraoK, KolesnikovaL, UematsuY, GismondoMR, MurphyBR, RappuoliR, and LanzavecchiaA: An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nat Med, 2004; 10:871–875.
88.
SmithK, GarmanL, WrammertJ, ZhengNY, CapraJD, AhmedR, and WilsonPC: Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc, 2009; 4:372–384.
89.
ObiakorH, SehgalD, DassoJF, BonnerRF, MalekafzaliA, and MageRG: A comparison of hydraulic and laser capture microdissection methods for collection of single B cells, PCR, and sequencing of antibody VDJ. Anal Biochem, 2002; 306:55–62.
90.
TillerT, MeffreE, YurasovS, TsuijiM, NussenzweigMC, and WardemannH: Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods, 2008; 329:112–124.
91.
LabrijnAF, JanmaatML, ReichertJM, and ParrenP: Bispecific antibodies: A mechanistic review of the pipeline. Nat Rev Drug Discov, 2019; 18:585–608.
92.
EsfahaniK, RoudaiaL, BuhlaigaN, Del RinconSV, PapnejaN, and MillerWHJr.: A review of cancer immunotherapy: From the past, to the present, to the future. Curr Oncol, 2020; 27:S87–S97.
93.
WahidB, AliA, RafiqueS, WaqarM, WasimM, WahidK, and IdreesM: An overview of cancer immunotherapeutic strategies. Immunotherapy, 2018; 10:999–1010.
94.
WaldmanAD, FritzJM, and LenardoMJ: A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol, 2020; 20:651–668.
95.
CoulsonA, LevyA, and Gossell-WilliamsM: Monoclonal antibodies in cancer therapy: Mechanisms, successes and limitations. West Indian Med J, 2014; 63:650–654.
96.
ParkR, WinnickiM, LiuE, and ChuWM: Immune checkpoints and cancer in the immunogenomics era. Brief Funct Genomics, 2019; 18:133–139.
97.
HargadonKM, JohnsonCE, and WilliamsCJ: Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol, 2018; 62:29–39.
98.
HeX, and XuC: Immune checkpoint signaling and cancer immunotherapy. Cell Res, 2020; 30:660–669.
99.
LeachDR, KrummelMF, and AllisonJP: Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996; 271:1734–1736.
100.
DasS, and JohnsonDB: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer, 2019; 7:306.
101.
HodiFS, Chiarion-SileniV, GonzalezR, GrobJJ, RutkowskiP, CoweyCL, LaoCD, SchadendorfD, WagstaffJ, DummerR, FerrucciPF, SmylieM, HillA, HoggD, Marquez-RodasI, JiangJ, RizzoJ, LarkinJ, and WolchokJD: Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol, 2018; 19:1480–1492.
102.
RotteA: Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res, 2019; 38:255.
103.
HegdeNR, RaoPP, BayryJ, and KaveriSV: Immunotherapy of viral infections. Immunotherapy, 2009; 1:691–711.
104.
HashimotoK, and HosoyaM: Neutralizing epitopes of RSV and palivizumab resistance in Japan. Fukushima J Med Sci, 2017; 63:127–134.
105.
SchickliJH, WhitacreDC, TangRS, KaurJ, LawlorH, PetersCJ, JonesJE, PetersonDL, McCarthyMP, Van NestG, and MilichDR: Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest, 2015; 125:1637–1647.
106.
IMpact-RSV-Study-Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics, 1998; 102:531–537.
YangL, LiuW, YuX, WuM, ReichertJM, and HoM: COVID-19 antibody therapeutics tracker: A global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther, 2020; 3:205–212.
SivapalasingamS, KamalM, SlimR, HosainR, ShaoW, StoltzR, YenJ, PologeLG, CaoY, PartridgeM, SumnerG, and LipsichL: Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: A randomised, first-in-human phase 1 study. Lancet Infect Dis, 2018; 18:884–893.
DaveyRTJr., DoddL, ProschanMA, NeatonJ, Neuhaus NordwallJ, KoopmeinersJS, BeigelJ, TierneyJ, LaneHC, FauciAS, MassaquoiMBF, SahrF, and MalvyD: A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med, 2016; 375:1448–1456.
114.
ChoiJH, WooHM, LeeTY, LeeSY, ShimSM, ParkWJ, YangJS, KimJA, YunMR, KimDW, KimSS, ZhangY, ShiW, WangL, GrahamBS, MascolaJR, WangN, McLellanJS, LeeJY, and LeeH: Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus. PLoS One, 2020; 15:e0232757.
115.
CortiD, ZhaoJ, PedottiM, SimonelliL, AgnihothramS, FettC, Fernandez-RodriguezB, FoglieriniM, AgaticG, VanzettaF, GopalR, LangrishCJ, BarrettNA, SallustoF, BaricRS, VaraniL, ZambonM, PerlmanS, and LanzavecchiaA: Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A, 2015; 112:10473–10478.
116.
de WitE, FeldmannF, HorneE, OkumuraA, CameroniE, HaddockE, SaturdayG, ScottD, GopalR, ZambonM, CortiD, and FeldmannH: Prophylactic efficacy of a human monoclonal antibody against MERS-CoV in the common marmoset. Antiviral Res, 2019; 163:70–74.
117.
de WitE, FeldmannF, OkumuraA, HorneE, HaddockE, SaturdayG, ScottD, ErlandsonKJ, StahlN, LipsichL, KyratsousCA, and FeldmannH: Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res, 2018; 156:64–71.
118.
JohnsonRF, BagciU, KeithL, TangX, MolluraDJ, ZeitlinL, QinJ, HuzellaL, BartosCJ, BohorovaN, BohorovO, GoodmanC, KimDH, PaultyMH, VelascoJ, WhaleyKJ, JohnsonJC, PettittJ, OrkBL, SolomonJ, OberlanderN, ZhuQ, SunJ, HolbrookMR, OlingerGG, BaricRS, HensleyLE, JahrlingPB, and MarascoWA: 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology, 2016; 490:49–58.
119.
DuL, ZhaoG, YangY, QiuH, WangL, KouZ, TaoX, YuH, SunS, TsengCT, JiangS, LiF, and ZhouY: A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol, 2014; 88:7045–7053.
120.
LiY, WanY, LiuP, ZhaoJ, LuG, QiJ, WangQ, LuX, WuY, LiuW, ZhangB, YuenKY, PerlmanS, GaoGF, and YanJ: A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res, 2015; 25:1237–1249.
121.
PascalKE, ColemanCM, MujicaAO, KamatV, BaditheA, FairhurstJ, HuntC, StreinJ, BerrebiA, SiskJM, MatthewsKL, BabbR, ChenG, LaiKM, HuangTT, OlsonW, YancopoulosGD, StahlN, FriemanMB, and KyratsousCA: Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A, 2015; 112:8738–8743.
122.
WidjajaI, WangC, van HaperenR, Gutierrez-AlvarezJ, van DierenB, OkbaNMA, RajVS, LiW, Fernandez-DelgadoR, GrosveldF, van KuppeveldFJM, HaagmansBL, EnjuanesL, DrabekD, and BoschBJ: Towards a solution to MERS: Protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect, 2019; 8:516–530.
123.
JiangL, WangN, ZuoT, ShiX, PoonKM, WuY, GaoF, LiD, WangR, GuoJ, FuL, YuenKY, ZhengBJ, WangX, and ZhangL: Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med, 2014; 6:234ra259.
124.
TangXC, AgnihothramSS, JiaoY, StanhopeJ, GrahamRL, PetersonEC, AvnirY, TallaricoAS, SheehanJ, ZhuQ, BaricRS, and MarascoWA: Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A, 2014; 111:E2018–E2026.
125.
YingT, DuL, JuTW, PrabakaranP, LauCC, LuL, LiuQ, WangL, FengY, WangY, ZhengBJ, YuenKY, JiangS, and DimitrovDS: Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol, 2014; 88:7796–7805.
126.
NIH: A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051, 2017. https://clinicaltrials.gov/ct2/show/NCT03301090.
127.
TianX, LiC, HuangA, XiaS, LuS, ShiZ, LuL, JiangS, YangZ, WuY, and YingT: Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 2020; 9:382–385.
128.
WangC, LiW, DrabekD, OkbaNMA, van HaperenR, OsterhausA, van KuppeveldFJM, HaagmansBL, GrosveldF, and BoschBJ: A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun, 2020; 11:2251.
129.
ChenX, LiR, PanZ, QianC, YangY, YouR, ZhaoJ, LiuP, GaoL, LiZ, HuangQ, XuL, TangJ, TianQ, YaoW, HuL, YanX, ZhouX, WuY, DengK, ZhangZ, QianZ, ChenY, and YeL: Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol, 2020; 17:647–649.
130.
Noy-PoratT, MakdasiE, AlcalayR, MechalyA, LevyY, Bercovich-KinoriA, ZaubermanA, TamirH, Yahalom-RonenY, IsraeliM, EpsteinE, AchdoutH, MelamedS, ChitlaruT, WeissS, PeretzE, RosenO, ParanN, YitzhakiS, ShapiraSC, IsraelyT, MazorO, and RosenfeldR: A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat Commun, 2020; 11:4303.
131.
YuanM, WuNC, ZhuX, LeeCD, SoRTY, LvH, MokCKP, and WilsonIA: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science, 2020; 368:630–633.
132.
ShiR, ShanC, DuanX, ChenZ, LiuP, SongJ, SongT, BiX, HanC, WuL, GaoG, HuX, ZhangY, TongZ, HuangW, LiuWJ, WuG, ZhangB, WangL, QiJ, FengH, WangFS, WangQ, GaoGF, YuanZ, and YanJ: A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020; 584:120–124.
LvZ, DengYQ, YeQ, CaoL, SunCY, FanC, HuangW, SunS, SunY, ZhuL, ChenQ, WangN, NieJ, CuiZ, ZhuD, ShawN, LiXF, LiQ, XieL, WangY, RaoZ, QinCF, and WangX: Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science, 2020; 369:1505–1509.
135.
IyerAS, JonesFK, NodoushaniA, KellyM, BeckerM, SlaterD, MillsR, TengE, KamruzzamanM, Garcia-BeltranWF, AstudilloM, YangD, MillerTE, OliverE, FischingerS, AtyeoC, IafrateAJ, CalderwoodSB, LauerSA, YuJ, LiZ, FeldmanJ, HauserBM, CaradonnaTM, BrandaJA, TurbettSE, LaRocqueRC, MellonG, BarouchDH, SchmidtAG, AzmanAS, AlterG, RyanET, HarrisJB, and CharlesRC: Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol, 2020; 5:eabe0367.
136.
ChiX, YanR, ZhangJ, ZhangG, ZhangY, HaoM, ZhangZ, FanP, DongY, YangY, ChenZ, GuoY, ZhangJ, LiY, SongX, ChenY, XiaL, FuL, HouL, XuJ, YuC, LiJ, ZhouQ, and ChenW: A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science, 2020; 369:650–655.
ZostSJ, GilchukP, ChenRE, CaseJB, ReidyJX, TrivetteA, NargiRS, SuttonRE, SuryadevaraN, ChenEC, BinshteinE, ShrihariS, OstrowskiM, ChuHY, DidierJE, MacRenarisKW, JonesT, DayS, MyersL, Eun-Hyung LeeF, NguyenDC, SanzI, MartinezDR, RothlaufPW, BloyetLM, WhelanSPJ, BaricRS, ThackrayLB, DiamondMS, CarnahanRH, and CroweJEJr.: Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med, 2020; 26:1422–1427.
145.
RobbieGJ, CristeR, Dall'acquaWF, JensenK, PatelNK, LosonskyGA, and GriffinMP: A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother, 2013; 57:6147–6153.
146.
GriffinMP, KhanAA, EsserMT, JensenK, TakasT, KankamMK, VillafanaT, and DubovskyF: Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother, 2017; 61:e01714-16.
147.
YuXQ, RobbieGJ, WuY, EsserMT, JensenK, SchwartzHI, BellamyT, Hernandez-IllasM, and JafriHS: Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother, 2017; 61:e01020-16.
IsonMG: Therapeutic Effect of Regdanvimab (CT-P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection: eSymposia, Antibodies and Vaccines as Drugs for COVID-19, Virtual Key Stone Symposia, 2021. https://virtual.keystonesymposia.org/ks/sessions/6866/view. (Accessed January16, 2021).
ChenP, NirulaA, HellerB, GottliebRL, BosciaJ, MorrisJ, HuhnG, CardonaJ, MocherlaB, StosorV, ShawaI, AdamsAC, Van NaardenJ, CusterKL, ShenL, DuranteM, OakleyG, SchadeAE, SaboJ, PatelDR, KlekotkaP, SkovronskyDM, and InvestigatorsB-: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med, 2021; 384:229–237.
152.
GottliebRL, NirulaA, ChenP, BosciaJ, HellerB, MorrisJ, HuhnG, CardonaJ, MocherlaB, StosorV, ShawaI, KumarP, AdamsAC, Van NaardenJ, CusterKL, DuranteM, OakleyG, SchadeAE, HolzerTR, EbertPJ, HiggsRE, KallewaardNL, SaboJ, PatelDR, KlekotkaP, ShenL, and SkovronskyDM: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial. JAMA, 2021; 325, DOI: 10.1001/jama.2021.0202.
153.
FalaL: Portrazza (necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer. Am Health Drug Benefits, 2016; 9:119–122.
154.
Garcia-FoncillasJ, SunakawaY, AderkaD, WainbergZ, RongaP, WitzlerP, and StintzingS: Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors. Front Oncol, 2019; 9:849.
155.
DuboisEA, and CohenAF: Panitumumab. Br J Clin Pharmacol, 2009; 68:482–483.
156.
Crombet RamosT, Mestre FernandezB, Mazorra HerreraZ, and Iznaga EscobarNE: Nimotuzumab for patients with inoperable cancer of the head and neck. Front Oncol, 2020; 10:817.
157.
Kazazi-HyseniF, BeijnenJH, and SchellensJH: Bevacizumab. Oncologist, 2010; 15:819–825.
158.
WuJ, FuJ, ZhangM, and LiuD: Blinatumomab: A bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol, 2015; 8:104.
159.
RizzieriD: Zevalin((R)) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?. Crit Rev Oncol Hematol, 2016; 105:5–17.
160.
WeinerGJ: Rituximab: Mechanism of action. Semin Hematol, 2010; 47:115–123.
TobinaiK, KleinC, OyaN, and Fingerle-RowsonG: A review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther, 2017; 34:324–356.
164.
LambertJ, PautasC, TerreC, RaffouxE, TurlureP, CaillotD, LegrandO, ThomasX, GardinC, Gogat-MarchantK, RubinSD, BennerRJ, BoussetP, PreudhommeC, ChevretS, DombretH, and CastaigneS: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica, 2019; 104:113–119.
165.
SanchezL, WangY, SiegelDS, and WangML: Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol, 2016; 9:51.
166.
HavrdovaE, HorakovaD, and KovarovaI: Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. Ther Adv Neurol Disord, 2015; 8:31–45.
167.
GemmeteJJ, and MukherjiSK: Trastuzumab (herceptin). AJNR Am J Neuroradiol, 2011; 32:1373–1374.
168.
McDermottJ, and JimenoA: Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barc), 2015; 51:7–20.
169.
GuoL, ZhangH, and ChenB: Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer, 2017; 8:410–416.
170.
Gil-BazoI: Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer. Transl Lung Cancer Res, 2017; 6:S35–S38.
171.
FaienaI, CummingsAL, CrosettiAM, PantuckAJ, ChamieK, and DrakakiA: Durvalumab: An investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther, 2018; 12:209–215.
172.
LeeHT, LeeJY, LimH, LeeSH, MoonYJ, PyoHJ, RyuSE, ShinW, and HeoYS: Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep, 2017; 7:5532.
173.
MagenH, and MuchtarE: Elotuzumab: The first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol, 2016; 7:187–195.
174.
DhillonS: Dinutuximab: First global approval. Drugs, 2015; 75:923–927.
175.
TarhiniA, LoE, and MinorDR: Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm, 2010; 25:601–613.
